1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Amgen Delivers Mixed Data For Rocatinlimab In Atopic Dermatitis, Uplizna In Myasthenia Gravis

Four Of Seven More AD Trials To Read Out Over Next Year

 
• By Mandy Jackson

Rocatinlimab met its Phase III endpoints with results that appear uncompetitive with AD market leader Dupixent, while Uplizna may offer a compelling twice-yearly gMG treatment option.

Long Exposure Night Time Rocket Launch - Planet Earth with a spectacular sunset
HORIZON is the first of eight ROCKET studies in atopic dermatitis • Source: Shutterstock

Amgen, Inc. made an unusual move to release topline Phase III results for its Kyowa Kirin Co., Ltd.-partnered OX40 inhibitor rocatinlimab in atopic dermatitis (AD) and its CD19 inhibitor Uplizna (inebilizumab) in generalized myasthenia gravis (gMG), holding an analyst call after the stock market closed on 24 September and forgoing press releases. The clinical trials for both drugs delivered statistically significant results, but while most analysts saw a role for Uplizna in gMG, all questioned rocatinlimab’s ability to compete in AD.

Key Takeaways

  • Amgen reported the first Phase III results for OX40 inhibitor rocatinlimab in atopic dermatitis and CD19 inhibitor Uplizna (inebilizumab) in generalized myasthenia gravis, which generated mixed reactions.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Replimune CRL Could Hold Warning For Accelerated Approvals

 
• By Jessica Merrill

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 
• By Dexter Jie Yan

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

More from R&D

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

Pipeline Watch: Five Approvals And Twelve Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.